Paediatric Formulation: Design and Development
Material type:![Article](/opac-tmpl/lib/famfamfam/AR.png)
- books978-3-0365-0741-5
- 9783036507408
- 9783036507415
- Medicine
- dasatinib
- Duchenne muscular dystrophy
- cyclodextrin inclusion complex
- phase solubility studies
- paediatric age
- liquid formulation
- tumorspheres
- retinoblastoma
- topotecan
- penetration
- confocal microscopy
- poorly water soluble drug
- solubility enhancement
- grinding
- spray congealing
- neglected tropical diseases
- polymorph
- NorvirĀ®
- ritonavir
- poorly soluble compound
- pediatric
- palatability assessment
- bioavailability
- flavor profile
- Interleukin-1
- anakinra
- canakinumab
- innovative biotechnologies
- autoinflammatory disease
- Kawasaki disease
- systemic juvenile idiopathic arthritis
- personalized medicine
- child
- pediatrics
- neonates
- formulation
- product development
- formulation development
- oral
- parenteral
- topical
- inhaled
- intra nasal
- biopharmaceutics
- administration
- excipient
- NICU
- device
- medication error
- dosage form
- modified release
- drug delivery
- paediatric formulation development
- paediatric dosage forms
- chronic myeloid leukemia
- tyrosine kinase inhibitors
- pediatric age
- imatinib
- nilotinb
- ponatinib
- Orodispersible formulation
- pyrazinamide
- pediatric drug delivery
- tuberculosis
- design of experiments
- children
- edible films
- development
- design
- paediatric
- age-related
- palatable
- taste-masking
- acceptable
Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
![]() |
OPJGU Sonepat- Campus | E-Books Open Access | Available |
Open Access star Unrestricted online access
The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients.
Creative Commons https://creativecommons.org/licenses/by/4.0/ cc https://creativecommons.org/licenses/by/4.0/
English
There are no comments on this title.